Vanda Pharmaceuticals | VNDA - Fremdkapital

Aktienkurs
7.22
Täglich Wechseln
-0.11 -1.50%
Monatlich
-22.28%
Jährlich
74.82%
Q2 Prognose
7.02




Fremdkapital Veränderung Datum
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Akebia Therapeutics USD 48.25M 609K 2025-12
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Arrowhead Research USD 538.1M 323.22M 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Enanta Pharmaceuticals USD 0 0 2024-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Insmed USD 540.96M 1.24M 2025-12
J&J USD 39.44B 30M 2025-12
Lexicon Pharmaceuticals USD 49.41M 7.1M 2025-12
Ligand Pharmaceuticals USD 445.49M 445.44M 2025-09
Merck USD 39.97B 6B 2025-09
Minerva Neurosciences USD 0 86.58M 2024-09
Moderna USD 610M 584M 2025-12
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 15.72B 2.45B 2025-12
Takeda JPY 4.27T 81.29B 2025-12
Teva Pharmaceutical Industries USD 14.99B 1.78B 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12
Veracyte USD 0 0 2025-03